Speaking at the same news conference, he said he hoped the trial would be resumed later on Tuesday or Wednesday. We had an external event that led to the regulator being notified, Gorinchteyn said. On Tuesday, Anvisa said it would maintain the suspension and did not give any indication of how long it might last, adding it required more information on the incident. It has previously said it expects interim results of late-stage trials this year. Work has even begun on a plant capable of producing 100 million doses a year.
Anvisa said it expects the trial for the matter of the tool to be suspended for another 2 days.
( z0 say :ARG0 ( z1 organization :name ( z2 name :op "Anvisa" ) ) :ARG1 ( z3 expect :ARG0 z1 :ARG1 ( z4 suspend :ARG1 ( z5 try :ARG2 ( z6 matter :mod ( z7 tool ) ) ) :duration ( z8 temporal-quantity :quant 2 :mod ( z9 another ) :unit ( z10 day ) ) ) ) )
(z0 / say-01
    :ARG0 (z1 / organization
              :name (z2 / name
                        :op1 "Anvisa"))
    :ARG1 (z3 / expect-01
              :ARG0 z1
              :ARG1 (z4 / suspend-01
                        :ARG1 (z5 / try-02
                                  :ARG2 (z6 / matter
                                            :mod (z7 / tool)))
                        :duration (z8 / temporal-quantity
                                      :quant 2
                                      :mod (z9 / another)
                                      :unit (z10 / day)))))
Anvisa said it expects the trial for the matter of the tool to be suspended for another 2 days .
z1 :name z2
z2 :op1 1
z0 :ARG0 z1
z0 :ARG1 z3
z3 :ARG0 z1
z5 :ARG2 z6
z6 :mod z7
z4 :ARG1 z5
z3 :ARG1 z4
z8 :quant 0
z8 :mod z9
z4 :duration z8
z8 :unit z10